The changing epidemiology worldwide of<i>Mycobacterium ulcerans</i>

O’Brien, D. P.; Jeanne, Isabelle; Blasdell, Kim R.; Avumegah, Michael Selorm; Athan, Eugene

doi:10.1017/s0950268818002662

Cited by 44 publications

(44 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since 2010, the number of new cases of Buruli ulcer has decreased in several countries in which this disease is endemic, including Benin (appendix pp [1][2]. Surprisingly, no epidemiological study has been done to identify the factors underlying this decrease in Buruli ulcer incidence, but several hypotheses have been put forward, [15][16][17] including: (1) the exhaustive diagnosis of chronic and active cases combined with active screening and treat ment campaigns since 2007; (2) changes to the environmental reservoir of M ulcerans; (3) the introduction of medical treatments (antibiotics), suggesting a role for humans as a reservoir of the bacterium; and (4) a decrease in high-risk activities involving contact with M ulcerans, due to the use of protected water sources.…”

Section: Introductionmentioning

confidence: 99%

Effect of well drilling on Buruli ulcer incidence in Benin: a case-control, quantitative survey

Degnonvi

Fleuret

Coudereau

et al. 2019

The Lancet Planetary Health

View full text Add to dashboard Cite

Background Buruli ulcer is the third most common mycobacterial disease worldwide. The public health burden of this neglected tropical disease is large, particularly in poor areas of west and central Africa. The development of appropriate preventive strategies is hampered by an incomplete understanding of the epidemiology and transmission of the disease. We investigated the effect of the drilling of wells on Buruli ulcer incidence. Methods In this case-control, quantitative survey, we obtained field data for Buruli ulcer incidence over a 10-year period from a specialised centre that collected data for the Ouémé and Plateau departments in Benin, and data for well drilling from the Ministry of Energy, Water and Mines in Benin. The coordinates of the wells drilled were obtained during site visits. A case-control study was then done to investigate the role of well water use in protecting against Buruli ulcer. Findings We found a strong inverse correlation between the incidence of Buruli ulcer and the number of new wells drilled in the Bonou municipality (r 2 =0•8818). A case-control study (106 cases and 212 controls) showed that regular use of the water from the wells for washing, bathing, drinking, or cooking was protective against Buruli ulcer (adjusted odds ratio 0•1, 95% CI 0•04-0•44; p=0•0012). Interpretation This study opens up new possibilities for developing an effective yet affordable policy to fight the disease on a substantial geographical scale. Our study shows that providing access to protected water is an efficient and feasable way to reduce the incidence of Buruli ulcer.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of well drilling on Buruli ulcer incidence in Benin: a case-control, quantitative survey

Degnonvi

Fleuret

Coudereau

et al. 2019

The Lancet Planetary Health

View full text Add to dashboard Cite

show abstract

“…M. ulcerans was first described as the causative agent of Buruli ulcer in Victoria, Australia, in 1948 (14), while descriptions of ulcerative lesions probably caused by M. ulcerans in Africa, namely Uganda, date back to the late 18th century. Formal description and reporting of cases on the continent of Africa occurred during the 1950s and 1960s (15). Buruli ulcer has been reported in 33 countries worldwide, occurring mainly in West Africa and southeastern Australia (1).…”

mentioning

confidence: 99%

Global Epidemiology of Buruli Ulcer, 2010–2017, and Analysis of 2014 WHO Programmatic Targets

Omansen¹,

Erbowor-Becksen²,

Yotsu³

et al. 2019

Emerg. Infect. Dis.

View full text Add to dashboard Cite

Buruli ulcer is a neglected tropical disease caused by Myocobacterium ulcerans; it manifests as a skin lesion, nodule, or ulcer that can be extensive and disabling. To assess the global burden and the progress on disease control, we analyzed epidemiologic data reported by countries to the World Health Organization during 2010–2017. During this period, 23,206 cases of Buruli ulcer were reported. Globally, cases declined to 2,217 in 2017, but local epidemics seem to arise, such as in Australia and Liberia. In 2013, the World Health Organization formulated 4 programmatic targets for Buruli ulcer that addressed PCR confirmation, occurrence of category III (extensive) lesions and ulcerative lesions, and movement limitation caused by the disease. In 2014, only the movement limitation goal was met, and in 2019, none are met, on a global average. Our findings support discussion on future Buruli ulcer policy and post-2020 programmatic targets.

show abstract

“…Buruli ulcer (BU) is a disease caused by the bacteria Mycobacterium ulcerans and has been reported in the tropics and sub-tropics of over 33 countries [1], with very few cases reported in temperate areas [2,3]. Disease progression is marked by destruction of the subcutaneous skin layer, which sometimes damages nerves and blood vessels [4,5].…”

Section: Introductionmentioning

confidence: 99%

“…The destructive nature of the disease has been attributed to mycolactone, a macrolide toxin produced by the bacillus which causes apoptosis of cells [6,7]. Although a recent report indicates a 64% reduction in BU cases globally in the last 9 years [1], the incidence in Australia has increased 248% within the same time period [1]. A steady decline has been observed in endemic areas of West Africa (Ghana, Benin and Cote d'Ivoire) except in Nigeria where cases appear to be on the rise [1,8].…”

Section: Introductionmentioning

confidence: 99%

Cell-mediated and serology-based tests for Mycobacterium ulcerans disease: A systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Buruli ulcer (BU) is a subcutaneous necrotic infection of the skin caused by Mycobacterium ulcerans. It is the third most common human mycobacterial disease after tuberculosis (TB) and leprosy. The available methods for detection of the bacilli in lesions are microscopic detection, isolation and cultivation of the bacterium, histopathology, and polymerase chain reaction (PCR). These methods, although approved by the World Health Organization (WHO), have infrastructural and resource challenges in medical centres and cell-mediated immunity (CMI) and/or serology-based tests have been suggested as easier and more appropriate for accurate assessment of the disease, especially in remote or underdeveloped areas. This study systematically reviewed and conducted a meta-analysis for all research aimed at developing cell-mediated immunity (CMI) and/or serology-based tests for M. ulcerans disease. Information for this review was searched through PubMed and Web of Science databases and identified up to June 2019. References from relevant articles and reports from the WHO Annual Meeting of the Global Buruli Ulcer Initiative were also used. Twelve studies beginning in 1952, that attempted to develop CMI and/or serology-based tests for the disease were identified. These studies addressed issues of specificity and sensitivity in context of antigen composition as well as study heterogeneity and bias. The two main types of antigenic preparations considered were pathogen-derived and recombinant protein preparations. There was slight difference in test performance when M. ulcerans recombinant proteins [positivity: 67.5%; 32.5%] or pathogenderived [positivity: 76.0%; 24.0%] preparations were used as test antigens among BU patients. However, pathogen-derived preparations were better at differentiating between patients and control groups [odds ratio (OR) of 27.92, 95%CI: 5.05-154.28]. This was followed by tests with the recombinant proteins [OR = 1.23, 95%CI: 0.27-5.62]. Overall, study heterogeneity index, I 2 was 92.4% (p = 0.000). It is apparent from this review that standardisation is needed in any future CMI and/or serology-based tests used for M. ulcerans disease. PLOS NEGLECTED TROPICAL DISEASESPLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008172 April 6, 2020 1 / 15 OPEN ACCESS Citation: Avumegah MS, Waidyatillake NT, Michalski WP, O'Brien DP, Nelson TM, Athan E (2020) Cell-mediated and serology-based tests for Mycobacterium ulcerans disease: A systematic review and meta-analysis. PLoS Negl Trop Dis 14 (4): e0008172. https://doi.org/10.Buruli ulcer (BU) is a debilitating skin infection caused by M. ulcerans. It is the third most common mycobacterial disease after tuberculosis and leprosy. BU is mainly restricted to the tropical and subtropical countries of the world, though temperate regions report sporadic cases. Polymerase chain reaction targeting IS2404 is the gold standard for M. ulcerans disease diagnosis and other methods such as histopathology, acid fast staining and microscopy are used for valid...

show abstract

The changing epidemiology worldwide ofMycobacterium ulcerans

Cited by 44 publications

References 94 publications

Effect of well drilling on Buruli ulcer incidence in Benin: a case-control, quantitative survey

Effect of well drilling on Buruli ulcer incidence in Benin: a case-control, quantitative survey

Global Epidemiology of Buruli Ulcer, 2010–2017, and Analysis of 2014 WHO Programmatic Targets

Cell-mediated and serology-based tests for Mycobacterium ulcerans disease: A systematic review and meta-analysis

Contact Info

Product

Resources

About